The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease

Australian and New Zealand Journal of Medicine

Volumn 30, Issue 1, 2000, Pages 48-53

  Reardon, K A ^a   Mendelsohn, F A O ^b   Chai, S Y ^b   Horne, Malcolm K ^a  

^a MONASH MEDICAL CENTRE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Angiotensin converting enzyme inhibitor; Clinical features; Dyskinesia; Motor fluctuations; Parkinson's disease; Perindopril

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CARBIDOPA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; LEVODOPA; PERINDOPRIL; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; MOVEMENT (PHYSIOLOGY); NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL;

EID: 0034023229     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2000.tb01054.x     Document Type: Article

References (15)

1. 1. Allen AM, Paxonos G, McKinley MJ, Chai SY, Mendelsohn FAO. Localization and characterisation of angiotensin II receptor binding sites in the human basal ganglia, thalamus, midbrain, pons, and cerebellum. J Comp Neurol 1991; 312: 291-8.
2. 2. Allen AM, MacGregor DP, Chai SY et al. Angiotensin II receptor binding associated with nigrostriatal and dopaminergic neurons in human basal ganglia. Ann Neurol 1992; 32: 334-9.
3. 3. Simonnet G, Giorguieff-Chesselet MF. Stimulating effect of angiotensin II on the spontaneous release of newly synthesised [3H]Dopamine in rat striatal slices. Neurosci Lett 1979; 15: 153-8.
4. 4. Dwoskin LP, Jewell AL, Cassis LA. DuP 753, a non-peptide angiotensin II-I receptor antagonist, alters dopaminergic function in the rat striatum. Naunyn Schmiedeberg's Arch Pharmacol 1992; 345: 153-9.
5. 5. Mendelsohn FAO, Jenkins TA, Berkovic SF. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res 1993; 613: 221-9.
6. 6. Jenkins TA, Chai SY, Howells DW, Mendelsohn FAO. Intrastriatal angiotensin II induces turning behaviour in 6-hydroxydopamine lesioned rats. Brain Res 1995; 691: 213-6.
7. 7. Georgiev V, Gyorgy L, Getova D, Markovska V. Some central effects of angiotensin II. Interactions with dopaminergic transmission. Acta Physiol Pharmacol Bulg 1985; 11: 19-26.
8. 8. Sudilovsky A, Turnball BA, Miller LH et al. Attenuation of apomorphine induced stereotypy by captopril pretreatment (Abstr.). Soc Neuroci 1983; 9 (Part 1): 132.
9. 9. Chai SY, McKenzie JS, McKinley MJ, Mendelsohn FAO. Angiotensin converting enzyme in the human basal forebrain and midbrain visualised by in vitro autoradiography. J Comp Neurol 1990; 291: 179-94.
10. 10. Skidgel RA, Defendini R, Erdos EG. Antiotensin I converting enzyme and its role in neuropeptide metabolism. In: Turner AJ (Ed.). Neuropeptides and their peptidases. New York: Ellis Horwood, 1987; 165-82.
11. 11. Jenkins TA, Mendelsohn FAO, Chai SY. Angiotensin converting enzyme modulates dopamine turnover in the striatum. J Neurochem 1997; 68: 1304-11.
12. 12. Hoehn MM, Yahir MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 424-7.
13. 13. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 430-4.
14. 14. Sigmaplot for windows. ©Jandel Corporation 1985-1993.
15. 15. Sakaguchi K, Chai SY, Jackson B, Johnston CI, Mendelsohn FAO. Neuroendocrinology 1988; 48: 223-8.